Health Canada Has Authorized CSL’s ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE).

Our Focus on Rare Serious Diseases

Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.